Status:
APPROVED_FOR_MARKETING
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Lead Sponsor:
Regeneron Pharmaceuticals
Conditions:
Non-Small Cell Lung Cancer (NSCLC)
Basal Cell Carcinoma (BCC)
Eligibility:
All Genders
Brief Summary
Provide expanded access of cemiplimab in patients with solid tumors
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.
Eligibility Criteria
Inclusion
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06132191
Last Update
November 20 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.